What is Calquence (acalabrutinib) and how is it used in mantle cell lymphoma?
Calquence (acalabrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor used to treat certain blood cancers, including mantle cell lymphoma (MCL). In MCL, it is used based on the specific patient setting defined by regulatory labeling (for example, whether the disease is newly diagnosed or relapsed/refractory, and whether the patient has had prior BTK-inhibitor treatment).
For which patients with mantle cell lymphoma is Calquence typically considered?
Use of Calquence in mantle cell lymphoma depends on the approved indication for the patient’s disease stage and prior therapy history, since MCL treatment strategies differ for:
- newly diagnosed versus relapsed/refractory disease
- patients who are fit enough for certain chemotherapy-based regimens versus those who need targeted therapy options
- prior lines of therapy, including prior exposure to other BTK inhibitors (which can affect subsequent choices)
How does a BTK inhibitor like Calquence work in mantle cell lymphoma?
Mantle cell lymphoma cells rely in part on B-cell receptor signaling pathways. Calquence blocks BTK, a key component in that signaling cascade, which can reduce lymphoma cell survival and proliferation.
What side effects do patients ask about with Calquence?
Patients commonly ask about side effects that are typical of BTK inhibitors, including effects related to bleeding risk, infections, and blood count changes. The specific risks and monitoring requirements vary by patient factors (other medicines, age, baseline blood counts, and infection risk).
What happens if Calquence doesn’t control mantle cell lymphoma?
If MCL does not respond or stops responding, clinicians generally reassess the treatment plan based on:
- whether the disease is refractory to the drug’s mechanism
- patient tolerance and safety issues
- available next-line options (often other targeted agents, combinations, or clinical trials, depending on what’s approved and appropriate)
Are patents or exclusivity relevant for Calquence’s availability in MCL?
Patent status can affect timing of generic or biosimilar-like competition for branded oncology drugs. For Calquence, DrugPatentWatch.com tracks patent and exclusivity information; you can check Calquence’s status there: https://www.drugpatentwatch.com/ .
Sources
- DrugPatentWatch.com – Calquence patent/exclusivity tracker